Aura Biosciences Files 8-K
Ticker: AURA · Form: 8-K · Filed: Oct 17, 2024 · CIK: 1501796
| Field | Detail |
|---|---|
| Company | Aura Biosciences, INC. (AURA) |
| Form Type | 8-K |
| Filed Date | Oct 17, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory
TL;DR
Aura Biosciences filed a routine 8-K, no major news yet.
AI Summary
Aura Biosciences, Inc. filed an 8-K on October 17, 2024, reporting on other events and financial statements. The filing does not contain specific details about new material events, significant financial figures, or material agreements within the provided text.
Why It Matters
This filing indicates Aura Biosciences is providing updates to the SEC, which could include routine disclosures or information relevant to investors monitoring the company's regulatory compliance.
Risk Assessment
Risk Level: low — The provided text is a standard 8-K filing notification without specific material events, making the immediate risk assessment low.
Key Players & Entities
- Aura Biosciences, Inc. (company) — Registrant
- October 17, 2024 (date) — Date of earliest event reported
- 001-40971 (other) — Commission File Number
- 32-0271970 (other) — IRS Employer Identification No.
- 80 Guest Street, Boston, Massachusetts 02135 (address) — Principal Executive Offices
- 617 500-8864 (phone_number) — Registrant's Telephone Number
FAQ
What specific items are being reported in this 8-K filing?
The filing indicates it covers 'Regulation FD Disclosure', 'Other Events', and 'Financial Statements and Exhibits'.
When was the earliest event reported in this filing?
The earliest event reported is dated October 17, 2024.
What is Aura Biosciences, Inc.'s principal executive office address?
The principal executive offices are located at 80 Guest Street, Boston, Massachusetts 02135.
What is the Commission File Number for Aura Biosciences, Inc.?
The Commission File Number is 001-40971.
What is the SIC code for Aura Biosciences, Inc.?
The Standard Industrial Classification (SIC) code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 1,152 words · 5 min read · ~4 pages · Grade level 14.4 · Accepted 2024-10-17 17:10:59
Key Financial Figures
- $0.00001 — nge on which registered Common Stock, $0.00001 par value per share AURA The Nasdaq
Filing Documents
- d818130d8k.htm (8-K) — 32KB
- d818130dex991.htm (EX-99.1) — 16KB
- d818130dex992.htm (EX-99.2) — 51KB
- g818130ex99_2p10g1.jpg (GRAPHIC) — 213KB
- g818130ex99_2p11g1.jpg (GRAPHIC) — 256KB
- g818130ex99_2p12g1.jpg (GRAPHIC) — 104KB
- g818130ex99_2p13g1.jpg (GRAPHIC) — 248KB
- g818130ex99_2p14g1.jpg (GRAPHIC) — 341KB
- g818130ex99_2p15g1.jpg (GRAPHIC) — 216KB
- g818130ex99_2p16g1.jpg (GRAPHIC) — 269KB
- g818130ex99_2p17g1.jpg (GRAPHIC) — 231KB
- g818130ex99_2p18g1.jpg (GRAPHIC) — 200KB
- g818130ex99_2p19g1.jpg (GRAPHIC) — 284KB
- g818130ex99_2p1g1.jpg (GRAPHIC) — 329KB
- g818130ex99_2p20g1.jpg (GRAPHIC) — 358KB
- g818130ex99_2p21g1.jpg (GRAPHIC) — 252KB
- g818130ex99_2p22g1.jpg (GRAPHIC) — 324KB
- g818130ex99_2p23g1.jpg (GRAPHIC) — 344KB
- g818130ex99_2p24g1.jpg (GRAPHIC) — 422KB
- g818130ex99_2p25g1.jpg (GRAPHIC) — 327KB
- g818130ex99_2p26g1.jpg (GRAPHIC) — 494KB
- g818130ex99_2p27g1.jpg (GRAPHIC) — 340KB
- g818130ex99_2p28g1.jpg (GRAPHIC) — 360KB
- g818130ex99_2p29g1.jpg (GRAPHIC) — 532KB
- g818130ex99_2p2g1.jpg (GRAPHIC) — 597KB
- g818130ex99_2p30g1.jpg (GRAPHIC) — 626KB
- g818130ex99_2p31g1.jpg (GRAPHIC) — 271KB
- g818130ex99_2p32g1.jpg (GRAPHIC) — 40KB
- g818130ex99_2p33g1.jpg (GRAPHIC) — 358KB
- g818130ex99_2p34g1.jpg (GRAPHIC) — 41KB
- g818130ex99_2p35g1.jpg (GRAPHIC) — 88KB
- g818130ex99_2p36g1.jpg (GRAPHIC) — 365KB
- g818130ex99_2p37g1.jpg (GRAPHIC) — 246KB
- g818130ex99_2p38g1.jpg (GRAPHIC) — 327KB
- g818130ex99_2p39g1.jpg (GRAPHIC) — 300KB
- g818130ex99_2p3g1.jpg (GRAPHIC) — 240KB
- g818130ex99_2p40g1.jpg (GRAPHIC) — 347KB
- g818130ex99_2p41g1.jpg (GRAPHIC) — 426KB
- g818130ex99_2p4g1.jpg (GRAPHIC) — 268KB
- g818130ex99_2p5g1.jpg (GRAPHIC) — 422KB
- g818130ex99_2p6g1.jpg (GRAPHIC) — 342KB
- g818130ex99_2p7g1.jpg (GRAPHIC) — 424KB
- g818130ex99_2p8g1.jpg (GRAPHIC) — 447KB
- g818130ex99_2p9g1.jpg (GRAPHIC) — 308KB
- 0001193125-24-238959.txt ( ) — 18052KB
- aura-20241017.xsd (EX-101.SCH) — 3KB
- aura-20241017_lab.xml (EX-101.LAB) — 18KB
- aura-20241017_pre.xml (EX-101.PRE) — 11KB
- d818130d8k_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements Any forward-looking statements are neither promises nor guarantees, and investors should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond the Company's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, without limitation, uncertainties inherent in clinical trials and in the availability and timing of data from ongoing clinical trials; the expected timing for submissions for regulatory approval or review by go
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release Dated October 17, 2024. 99.2 Virtual Urologic Oncology Investor Event Presentation of the Company. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aura Biosciences, Inc. Date: October 17, 2024 By: /s/ Elisabet de los Pinos Elisabet de los Pinos President and Chief Executive Officer